In a publication, Harui A, et al. encapsulated the anti-CTLA-4 antibody within a hydrogel matrix and administered it via peri-tumor injection to achieve the sustained perfusion of tumor-draining lymph nodes [87]. The gene discussed is CTLA4; the disease is neoplasm.